Vortex Energy Aktie - VRTX

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

0,075

Gebot

0,06

Fragen

0,07

Volumen

0,00 Tagesbereich 0,00

0,04 52-Wochen-Bereich 0,28

Handelsende

0,075

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

75.944

Finanzvolumen

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.015	25	0.06	0.075	0.06	24680	0.07299695	CS
4	-0.025	-25	0.1	0.145	0.06	29906	0.07832253	CS
12	0.025	50	0.05	0.15	0.04	75944	0.06209386	CS
26	-0.035	-31.8181818182	0.11	0.15	0.04	111694	0.06160354	CS
52	-0.19	-71.6981132075	0.265	0.28	0.04	90797	0.10923827	CS
156	-0.025	-25	0.1	2.32	0.04	184836	0.84751345	CS
260	-0.025	-25	0.1	2.32	0.04	184836	0.84751345	CS

VRTX - Frequently Asked Questions (FAQ)

What is the current Vortex Energy share price?

The current share price of Vortex Energy is $ 0,075

What is the 1 year trading range for Vortex Energy share price?

Vortex Energy has traded in the range of $ 0,04 to $ 0,28 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ADONAdonis Minerals Corp	$ 0,15 (114,29%)	6k
NIRVNirvana Life Sciences Inc	$ 0,30 (100,00%)	4,74k
IANiAnthus Capital Holdings Inc	$ 0,01 (100,00%)	15k
OBRNOberon Uranium Corp	$ 0,015 (50,00%)	87,48k
HYTNHYTN Innovations Inc	$ 0,29 (38,10%)	102,5k
CSSCascada Silver Corp	$ 0,005 (-50,00%)	551,87k
BBMBlueberries Medical Corporation	$ 0,005 (-50,00%)	74,7k
TEMPTempus Capital Inc	$ 0,04 (-38,46%)	10k
SCYBScryb Inc	$ 0,01 (-33,33%)	20k
MBIOMindBio Therapeutics Corp	$ 0,01 (-33,33%)	673,5k
HUNTGold Hunter Resources Inc	$ 0,10 (17,65%)	1,07M
CACRKWG Resources Inc	$ 0,035 (0,00%)	842,55k
MBIOMindBio Therapeutics Corp	$ 0,01 (-33,33%)	673,5k
QMETQ Precious & Battery Metals Corp	$ 0,055 (-15,38%)	607,48k
QIMCQuebec Innovative Materials Corp	$ 0,22 (-10,20%)	561,05k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Vortex Energy Corp (VRTX)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

VRTX Neueste Nachrichten

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

VRTX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Vortex Energy Corp (VRTX) Börsenkurse

Vortex Energy Corp (VRTX)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

VRTX Neueste Nachrichten

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

VRTX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen